Evidence map›Paper›PMID 39698294›Full record

ArticleACS pharmacology & translational science2024

Long-Term Treatment with Fluoroethylnormemantine (FENM) Alleviated Memory Deficits, Amyloid Pathology, and Microglial Reaction in APP/PS1 Mice.

Aline Freyssin, Allison Carles, Barbara Moha, Gilles Rubinstenn, Tangui Maurice

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aline FreyssinMMDN, University of Montpellier, EPHE, INSERM, Montpellier and ReST Therapeutics, Paris 75006, France.
Allison CarlesMMDN, University of Montpellier, EPHE, INSERM, Montpellier, Paris 75006, France.
Barbara MohaMMDN, University of Montpellier, EPHE, INSERM, Montpellier, Paris 75006, France.
Gilles RubinstennReST Therapeutics, Montpellier 34095, France.
Tangui MauriceMMDN, University of Montpellier, EPHE, INSERM, Montpellier, Paris 75006, France.ORCID https://orcid.org/0000-0002-4074-6793

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fluoroethylnormemantine (FENM, RST-01) shows different pharmacological properties from Memantine. The drug is neuroprotective in pharmacological and transgenic mouse models of Alzheimer's disease (AD), particularly limiting the neuroinflammatory response to amyloid-β (Aβ) accumulation. In order to define early therapeutic intervention aimed at preventing AD and targeting the early activation of proinflammatory pathways, we examined the impact of chronic FENM treatment starting presymptomatically in APP

Identifiers

PMID39698294
PMCPMC11650732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.